Pcas SA
PAR:PCA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Dell Technologies Inc
NYSE:DELL
|
Technology
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Abercrombie & Fitch Co
NYSE:ANF
|
Retail
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
S&P Global Inc
NYSE:SPGI
|
Financial Services
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Citigroup Inc
NYSE:C
|
Banking
|
| IE |
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Pharmaceuticals
|
| US |
|
Medpace Holdings Inc
NASDAQ:MEDP
|
Life Sciences Tools & Services
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8
8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Dell Technologies Inc
NYSE:DELL
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Abercrombie & Fitch Co
NYSE:ANF
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
S&P Global Inc
NYSE:SPGI
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Citigroup Inc
NYSE:C
|
US |
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
IE |
|
|
Medpace Holdings Inc
NASDAQ:MEDP
|
US |
This alert will be permanently deleted.
Pcas SA
Pcas SA
Revenue
Pcas SA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pcas SA
PAR:PCA
|
Revenue
€230m
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Sartorius Stedim Biotech SA
PAR:DIM
|
Revenue
€2.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
|
|
Eurofins-Cerep SA
PAR:ALECR
|
Revenue
€46.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
8%
|
|
Pcas SA
Glance View
PCAS SA engages in the development, manufacture, and sale of chemicals. The company is headquartered in Ecully, Auvergne-Rhone-Alpes. The company operates through nine production sites and two main business units, Pharma Synthesis and Fine & Specialty Chemicals. Pharma Synthesis unit specializes in active pharmaceutical ingredients (API), intermediates and building blocks, and early phase services, among others. Fine & Specialty Chemicals unit focuses on custom manufacturing and proprietary products, such as fragrance, flavor ingredients, imaging and microelectronics chemicals. The firm operates several subsidiaries, including Saint-Jean Photochimie, Societe Bearnaise de Synthese, Expansia, PCAS BioMatrix Inc, based in Canada, and PCAS Finland Oy, based in Finland, among others.
See Also
What is Pcas SA's Revenue?
Revenue
230m
EUR
Based on the financial report for Jun 30, 2023, Pcas SA's Revenue amounts to 230m EUR.
What is Pcas SA's Revenue growth rate?
Revenue CAGR 10Y
3%
Over the last year, the Revenue growth was 21%. The average annual Revenue growth rates for Pcas SA have been 4% over the past three years , 2% over the past five years , and 3% over the past ten years .
You don't have any saved screeners yet
